Item 1.01. Entry Into a Material Definitive Agreement.
On November 18, 2019, Aevi Genomic Medicine, Inc. (the "Company") entered into
an agreement with The Children's Hospital of Philadelphia ("CHOP") to extend the
maturity date of that certain Secured Convertible Promissory Note dated as of
March 29, 2019 (the "Note"), issued by the Company to CHOP in the original
principal amount of $3,166,666.64 (the "Agreement"). Pursuant to the Agreement,
the maturity of the Note was extended until December 15, 2019, with an automatic
further extension to February 15, 2020, upon the occurrence of certain
circumstances. In addition, pursuant to the Agreement, the principal amount of
the Note was increased to $4,354,166.63, and will increase to $4,749,999.96 on
December 15, 2019 if the automatic extension is triggered and to $5,145,833.29
if the Note is still outstanding on January 15, 2020.
The foregoing description of the Agreement does not purport to be complete and
is qualified in its entirety by reference to the full text of the Agreement, a
copy of which the Company expects to file as an exhibit to the Company's Annual
Report on Form 10-K for the year ending December 31, 2019.
© Edgar Online, source Glimpses
AEVI GENOMIC MEDICINE, INC. 
